Tritoqualine

Summary

Tritoqualine (CHEMBL2104445) is an approved small molecule (ATC R06AX21); indicated across 1 condition including allergic disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: R06AX21
• Indications: 1 condition
• Chemistry: 500.5 Da · C26H32N2O8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2104445
Name	Tritoqualine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	72145
ATC	R06AX21
Molecular formula	C26H32N2O8
Molecular weight	500.5
InChIKey	IRGJVQIJENCTQF-UHFFFAOYSA-N

SMILES: CCOC1=C(C(=C(C2=C1C(OC2=O)C3C4=C(C5=C(C=C4CCN3C)OCO5)OC)N)OCC)OCC

IUPAC name: 7-amino-4,5,6-triethoxy-3-(4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3H-2-benzofuran-1-one

Also known as: 35NZ, 554L, Hypostamin, Hypostamine, Inhibostamin, L-554, Livalfa, MCI-5011, Tritocaline, Tritocualina, Tritoqualine, TRITOQUALINE

Patent coverage: 339 distinct patent families (1,180 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,160 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
allergic disease	4	MONDO:0005271	MONDO:0005271

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).